Home | PHARMAC
Home | PHARMAC
  • Website
  • Application Tracker
  • Schedule
  • About PHARMAC
    • About PHARMAC
    • Your guide to PHARMAC
    • Our history
    • Our people
    • Expert advice
    • PHARMAC's performance
    • Operating policies and procedures
    • Year in review 2017
    • Strategies
    • Consumer voice - review 2018
  • Medicines
    • Medicines
    • How medicines are funded
    • Medicines information
    • My medicine or medical device has changed
    • Your health
    • Hospital pharmaceuticals
    • New medicines – from development to funding
    • Equity
  • Hospital devices
    • Hospital devices
    • What's happening in each category?
    • PHARMAC's approach to hospital devices
    • Device Advice
    • PHARMAC medical devices forums 2017
  • News
  • Te Whaioranga
    • Te Whaioranga
    • Te Whaioranga 2013 - 2023: Māori Responsiveness Strategy
    • Whānau Ora
    • He Rongoā Pai, He Oranga Whānau
    • One Heart Many Lives
    • Scholarships
    • Hauora Arotahi - Māori health areas of focus
    • Māori Responsiveness Team
  • Pacific
    • Pacific
    • Pacific responsiveness strategy
    • Pacific action plan
  • Tools & resources
    • Tools & resources
    • Pharmaceutical Schedule
    • Annual Procurement Plan
    • Forms
    • Research
    • Print and PDF resources
    • Glossary
    • PHARMAC labelling preferences
  • Information for…

<< Section B - Therapeutic Groups

Online Pharmaceutical Schedule - February 2019

Info

Vaccinations
    • Section B - Therapeutic Groups
    • TG1 - National Immunisation Schedule
    • TG2 - Vaccinations
    • TG3 - Vaccinations

Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine        [Xpharm]

Inj 30IU diphtheriatoxoid with 40IU tetanustoxoid, 25mcg pertussistoxoid, 25mcg pertussisfilamentoushaemagluttinin, 8 mcgpertactin, 80 D-AgUpoliovirus, 10mcghepatitisBsurfaceantigen in 0.5ml syringe

TICK Infanrix-hexa 2459396 $0.00 per 10

Funded for patients meeting any of the following criteria:

  1. Up to four doses for children up to and under the age of 10 for primary immunisation; or

  2. An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or

  3. Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Vaccinations
    • Section B - Therapeutic Groups
    • TG1 - National Immunisation Schedule
    • TG2 - Vaccinations
    • TG3 - Vaccinations

Haemophilus influenzae type B vaccine        [Xpharm]

Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml

TICK Hiberix 2087758 $0.00 per 1

One dose for patients meeting any of the following:

  1. For primary vaccination in children; or

  2. An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or

  3. For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Vaccinations
    • Section B - Therapeutic Groups
    • TG1 - National Immunisation Schedule
    • TG2 - Vaccinations
    • TG3 - Vaccinations

Influenza vaccine       

Inj 45 mcg in 0.5 ml syringe (trivalent vaccine) - Only on a prescription - No patient co-payment payable

TICK Influvac 2538458 $90.00 per 10
  1. is available each year for patients who meet the following criteria, as set by PHARMAC, for use if a funded quadrivalent influenza vaccine is not available:

    1. all people 65 years of age and over; or

    2. people under 65 years of age who:

      1. have any of the following cardiovascular diseases:

        1. ischaemic heart disease, or

        2. congestive heart failure, or

        3. rheumatic heart disease, or

        4. congenital heart disease, or

        5. cerebo-vascular disease; or

      2. have either of the following chronic respiratory diseases:

        1. asthma, if on a regular preventative therapy, or

        2. other chronic respiratory disease with impaired lung function; or

      3. have diabetes; or

      4. have chronic renal disease; or

      5. have any cancer, excluding basal and squamous skin cancers if not invasive; or

      6. have any of the following other conditions:

        1. autoimmune disease, or

        2. immune suppression or immune deficiency, or

        3. HIV, or

        4. transplant recipients, or

        5. neuromuscular and CNS diseases/disorders, or

        6. haemoglobinopathies, or

        7. on long term aspirin, or

        8. have a cochlear implant, or

        9. errors of metabolism at risk of major metabolic decompensation, or

        10. pre and post splenectomy, or

        11. down syndrome, or

      7. are pregnant; or

    3. children aged four years and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness;

    4. people under 18 years of age living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board);

    5. People under 18 years of age who have been displaced from their homes in Edgecumbe and the surrounding region;

    Unless meeting the criteria set out above, the following conditions are excluded from funding:

    1. asthma not requiring regular preventative therapy,

    2. hypertension and/or dyslipidaemia without evidence of end-organ disease.

  2. Contractors will be entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with their DHB for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

  3. Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.


Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) [Xpharm]

TICK Fluarix Tetra 2539586 $9.00 per 1
  1. INFLUENZA VACCINE – child aged 6 months to 35 months

    is available each year for patients aged 6 months to 35 months who meet the following criteria, as set by PHARMAC:

    1. have any of the following cardiovascular diseases

      1. ischaemic heart disease, or

      2. congestive heart failure, or

      3. rheumatic heart disease, or

      4. congenital heart disease, or

      5. cerebo-vascular disease; or

    2. have either of the following chronic respiratory diseases:

      1. asthma, if on a regular preventative therapy, or

      2. other chronic respiratory disease with impaired lung function; or

    3. have diabetes; or

    4. have chronic renal disease; or

    5. have any cancer, excluding basal and squamous skin cancers if not invasive; or

    6. have any of the following other conditions:

      1. autoimmune disease, or

      2. immune suppression or immune deficiency, or

      3. HIV, or

      4. transplant recipients, or

      5. neuromuscular and CNS diseases/disorders, or

      6. haemoglobinopathies, or

      7. on long term aspirin, or

      8. have a cochlear implant, or

      9. errors of metabolism at risk of major metabolic decompensation, or

      10. pre and post splenectomy, or

      11. down syndrome, or

    7. have been hospitalised for respiratory illness or have a history of significant respiratory illness;

    8. are living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board);

    9. have been displaced from their homes in Edgecumbe and the surrounding region;

    Unless meeting the criteria set out above, the following conditions are excluded from funding:

    1. asthma not requiring regular preventative therapy,

    2. hypertension and/or dyslipidaemia without evidence of end-organ disease.

  2. Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.


Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) - Only on a prescription - No patient co-payment payable

TICK Influvac Tetra 2538466 $90.00 per 10
  1. INFLUENZA VACCINE – people 3 years and over

    is available each year for patients aged 3 years and over who meet the following criteria, as set by PHARMAC:

    1. all people 65 years of age and over; or

    2. people under 65 years of age who:

      1. have any of the following cardiovascular diseases:

        1. ischaemic heart disease, or

        2. congestive heart failure, or

        3. rheumatic heart disease, or

        4. congenital heart disease, or

        5. cerebo-vascular disease; or

      2. have either of the following chronic respiratory diseases:

        1. asthma, if on a regular preventative therapy, or

        2. other chronic respiratory disease with impaired lung function; or

      3. have diabetes; or

      4. have chronic renal disease; or

      5. have any cancer, excluding basal and squamous skin cancers if not invasive; or

      6. have any of the following other conditions:

        1. autoimmune disease, or

        2. immune suppression or immune deficiency, or

        3. HIV, or

        4. transplant recipients, or

        5. neuromuscular and CNS diseases/disorders, or

        6. haemoglobinopathies, or

        7. are children on long term aspirin, or

        8. have a cochlear implant, or

        9. errors of metabolism at risk of major metabolic decompensation, or

        10. pre and post splenectomy, or

        11. down syndrome, or

      7. are pregnant; or

    3. children aged four years or less (but over three years) who have been hospitalised for respiratory illness or have a history of significant respiratory illness;

    4. people under 18 years of age living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board);

    5. People under 18 years of age who have been displaced from their homes in Edgecumbe and the surrounding region;

    Unless meeting the criteria set out above, the following conditions are excluded from funding:

    1. asthma not requiring regular preventative therapy,

    2. hypertension and/or dyslipidaemia without evidence of end-organ disease.

  2. Contractors will be entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with their DHB for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

  3. Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

About this site

  • Sitemap
  • Copyright
  • Disclaimer
  • Privacy statement
  • This site is operated by PHARMAC, the Pharmaceutical Management Agency.

Contact

  • Contact us
  • Twitter - PHARMACnz
  • Facebook - PHARMACnz
  • YouTube - PHARMACgovtnz
  • LinkedIn - Pharmaceutical Management Agency (PHARMAC)
  • Careers
  • Newsfeed

Back to top

New Zealand Government